Clinical Trials Browser

Phase 1/2 × INDUSTRY × Advanced Solid Cancers × Clear all

NCT02694822 2025-03-17

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Phase 1/2 Completed

89 enrolled 22 charts

Advanced Solid Cancers